Clinical Trial Update: 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of 5-fluorouracil/leucovorin with regorafenib for metastatic colorectal cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Regorafenib (regorafenib)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Metastatic Colorectal Cancer (CRC) | Phase 2 | Status: RECRUITING